Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A (guardian™ 3)
A Multi-Centre, Open-Label, Non-Controlled Trial on Safety and Efficacy of N8 in Previously Treated Paediatric Patients With Haemophilia A
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Rio de Janeiro, Brazil, 20211-030
- Novo Nordisk Investigational Site
-
-
Parana
-
Curitiba, Parana, Brazil, 80250-060
- Novo Nordisk Investigational Site
-
-
Sao Paulo
-
Campinas, Sao Paulo, Brazil, 13081970
- Novo Nordisk Investigational Site
-
São Paulo, Sao Paulo, Brazil, 05403-000
- Novo Nordisk Investigational Site
-
-
-
-
-
Milano, Italy, 20124
- Novo Nordisk Investigational Site
-
-
-
-
-
Shizuoka-shi, Shizuoka, Japan, 4208660
- Novo Nordisk Investigational Site
-
-
-
-
-
Vilnius, Lithuania, LT-08406
- Novo Nordisk Investigational Site
-
-
-
-
-
Skopje, Macedonia, The Former Yugoslav Republic of, 1000
- Novo Nordisk Investigational Site
-
-
-
-
-
Kuala Lumpur, Malaysia, 50400
- Novo Nordisk Investigational Site
-
-
-
-
-
Warszawa, Poland, 00-576
- Novo Nordisk Investigational Site
-
Wroclaw, Poland, 50-345
- Novo Nordisk Investigational Site
-
-
-
-
-
San Juan, Puerto Rico, 00935
- Novo Nordisk Investigational Site
-
-
-
-
-
Moscow, Russian Federation, 105077
- Novo Nordisk Investigational Site
-
Saint-Petersburg, Russian Federation, 191119
- Novo Nordisk Investigational Site
-
-
-
-
-
Belgrade, Serbia, 11000
- Novo Nordisk Investigational Site
-
-
-
-
-
Taipei, Taiwan, 40447
- Novo Nordisk Investigational Site
-
-
-
-
-
Adana, Turkey, 01130
- Novo Nordisk Investigational Site
-
Antalya, Turkey, 01010
- Novo Nordisk Investigational Site
-
Bornova-IZMIR, Turkey, 35100
- Novo Nordisk Investigational Site
-
Izmit, Turkey, 41380
- Novo Nordisk Investigational Site
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85016-7710
- Novo Nordisk Investigational Site
-
-
California
-
Orange, California, United States, 92868
- Novo Nordisk Investigational Site
-
Torrance, California, United States, 90502-2004
- Novo Nordisk Investigational Site
-
-
Florida
-
Tampa, Florida, United States, 33607
- Novo Nordisk Investigational Site
-
-
Georgia
-
Augusta, Georgia, United States, 30912
- Novo Nordisk Investigational Site
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Novo Nordisk Investigational Site
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Novo Nordisk Investigational Site
-
-
Michigan
-
Detroit, Michigan, United States, 48201
- Novo Nordisk Investigational Site
-
East Lansing, Michigan, United States, 48823
- Novo Nordisk Investigational Site
-
-
Missouri
-
Kansas City, Missouri, United States, 64108-4619
- Novo Nordisk Investigational Site
-
-
Nebraska
-
Omaha, Nebraska, United States, 68198-2168
- Novo Nordisk Investigational Site
-
-
New York
-
Brooklyn, New York, United States, 11201-5425
- Novo Nordisk Investigational Site
-
Valhalla, New York, United States, 10595
- Novo Nordisk Investigational Site
-
-
Ohio
-
Dayton, Ohio, United States, 45404
- Novo Nordisk Investigational Site
-
-
Oregon
-
Portland, Oregon, United States, 97239-3098
- Novo Nordisk Investigational Site
-
-
South Carolina
-
Charleston, South Carolina, United States, 29425
- Novo Nordisk Investigational Site
-
-
Texas
-
Fort Worth, Texas, United States, 76104
- Novo Nordisk Investigational Site
-
Houston, Texas, United States, 77030
- Novo Nordisk Investigational Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male patients with severe (baseline FVIII less than or equal to 1%) haemophilia A
- Age below 12 years and weight at least 11 kg
Exclusion Criteria:
- Surgery planned to occur during trial participation (exceptions are port placement, dental extractions, and minor, uncomplicated emergent procedures)
- Congenital or acquired coagulation disorders other than haemophilia A
- Any history of FVIII inhibitors (greater than or equal to 0.6 BU/mL)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: rFVIII
|
Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa.
The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections.
The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The Incidence Rate of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU))
Time Frame: The adverse events were collected throughout the trial, corresponding to an average of 138 days per subject.
|
The incidence rate of FVIII inhibitors was calculated by including all patients with inhibitors in the nominator and including all patients with a minimum 50 exposure plus any patients with less than 50 exposures but with inhibitors in denominator.
|
The adverse events were collected throughout the trial, corresponding to an average of 138 days per subject.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Frequency of Adverse Events (AEs)
Time Frame: The adverse events were collected throughout the trial, corresponding to an average of 138 days per subject
|
Adverse event was defined as events occurring after administration of trial product.
Severe AEs: considerable interference with subject's daily activities, unacceptable.
Moderate AEs: Marked symptoms, moderate interference with the patient's daily activities.
Mild AEs: No or transient symptoms, no interference with the patient's daily activities.
Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.
|
The adverse events were collected throughout the trial, corresponding to an average of 138 days per subject
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Santagostino E, Lentz SR, Misgav M, Brand B, Chowdary P, Savic A, Kilinc Y, Amit Y, Amendola A, Solimeno LP, Saugstrup T, Matytsina I. Safety and efficacy of turoctocog alfa (NovoEight(R)) during surgery in patients with haemophilia A: results from the multinational guardian clinical trials. Haemophilia. 2015 Jan;21(1):34-40. doi: 10.1111/hae.12518. Epub 2014 Oct 2.
- Ozelo MC. Updates from guardian: a comprehensive registration programme. Eur J Haematol. 2015 Dec;95 Suppl 81:22-9. doi: 10.1111/ejh.12648.
- Kulkarni R, Karim FA, Glamocanin S, Janic D, Vdovin V, Ozelo M, Rageliene L, Carboni E, Laguna P, Dobaczewski G, Seremetis S, Lindblom A, Santagostino E. Results from a large multinational clinical trial (guardian3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia. 2013 Sep;19(5):698-705. doi: 10.1111/hae.12165. Epub 2013 May 8.
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- NN7008-3545
- U1111-1113-7182 (Other Identifier: WHO)
- 2009-016383-36 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.